Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
Complete Title: A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients with Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)
Trial Phase: II
Investigator: David Zhen
This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Keywords:
- Neuroendocrine Tumor
- Neoplasms
- Carcinoid Tumor
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
II
David Zhen
RG1004456
NCT03891784
A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients with Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)
Neuroendocrine Tumor
Neoplasms
Carcinoid Tumor